Marcel Franco Mougenot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marcel Franco Mougenot has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ana Leticia Rodrigues Costa
Institute of Exact and Technological Sciences, Campus Florestal, Federal University of Vicosa (UFV), Rodovia LMG 818, km 6, Florestal 35690-000, MG, Brazil
1 shared publication - Juliano Coelho da Silveira
Department of Veterinary Medicine, Faculty of Animal Science and Food Engineering University of São Paulo Pirassununga Brazil
1 shared publication - Lucimara Gaziola de la Torre
University of Campinas
1 shared publication - Marcelo Lancellotti
Faculty of Pharmaceutical Sciences, State University of Campinas, Campinas 13083-871, Brazil
1 shared publication - Marimelia Aparecida Porcionatto
Department of Biochemistry, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
1 shared publication - Vanessa Sousa Pereira
Department of Materials and Bioprocesses Engineering, School of Chemical Engineering, University of Campinas, Campinas 13083-970, Brazil
1 shared publication
Latest Publications
- Open Access
- 22 September 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2008
Biomimetic Nanovesicles—Sources, Design, Production Methods, and Applications
Despite all the progress in the field of liposomes and nanoparticles for applications as drug and gene delivery systems, the specific targeting and immune system escape capabilities of these systems are still limited. Biomimetic nanovesicles emerged as a strategy to overcome these and other limitations associated with synthetic carriers, such as short circulation time, cytotoxicity, and difficulty in crossing biological barriers, since many of the desirable abilities of drug delivery systems are innate characteristics of biological vesicles. Thus, the question arises: would biomimetic nanovesicles be responsible for addressing these advances? It is currently known that biomimetic nanovesicles (BNV) can combine the intrinsic advantages of natural materials with the well-known production methods and controllability of synthetic systems. Besides, the development of the biotechnology and nanotechnology fields has provided a better understanding of the functionalities of biological vesicles and the means for the design and production of biomimetic nanovesicles (BNV). Based on this, this work will focus on tracking the main research on biomimetic nanovesicles (BNV) applied as drug and gene delivery systems, and for vaccines applications. In addition, it will describe the different sources of natural vesicles, the technical perspectives on obtaining them, and the possibility of their hybridization with synthetic liposomes.
- 22 September 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2008
Open AccessBiomimetic Nanovesicles—Sources, Design, Production Methods, and Applications
Despite all the progress in the field of liposomes and nanoparticles for applications as drug and gene delivery systems, the specific targeting and immune system escape capabilities of these systems are still limited. Biomimetic nanovesicles emerged as a strategy to overcome these and other limitations associated with synthetic carriers, such as short circulation time, cytotoxicity, and difficulty in crossing biological barriers, since many of the desirable abilities of drug delivery systems are innate characteristics of biological vesicles. Thus, the question arises: would biomimetic nanovesicles be responsible for addressing these advances? It is currently known that biomimetic nanovesicles (BNV) can combine the intrinsic advantages of natural materials with the well-known production methods and controllability of synthetic systems. Besides, the development of the biotechnology and nanotechnology fields has provided a better understanding of the functionalities of biological vesicles and the means for the design and production of biomimetic nanovesicles (BNV). Based on this, this work will focus on tracking the main research on biomimetic nanovesicles (BNV) applied as drug and gene delivery systems, and for vaccines applications. In addition, it will describe the different sources of natural vesicles, the technical perspectives on obtaining them, and the possibility of their hybridization with synthetic liposomes.